February 17th, 2023

adMare Bioinnovations and PRiME Next-Generation Precision Medicine Collaborate to Translate Academic Research into Life Changing Therapeutics

adMare BioInnovations and PRiME Next-Generation Precision Medicine, an Institutional Strategic Initiative at the University of Toronto, announce their new partnership to support the building of new Canadian life science companies and therapeutic products through the advancement of precision medicine research and commercialization. Through this partnership, adMare will work together with PRiME and University of Toronto’s Innovation and Partnerships Office (IPO) to identify innovative research and early technologies made across the university that have the potential to be collaboratively translated into new therapeutic products and other novel health innovations...READ MORE

Leading Universities Adopt BioTalent Canada’s Skills Courses to Improve Student Job-Readiness

BioTalent Canada is pleased to announce that several leading Canadian post-secondary institutions are adopting its Essential and Technical Skills Fundamentals courses and offering them to their students. Memorandums of Understanding (MOUs) have been signed between BioTalent Canada and the University of Ottawa, University of Waterloo, University of Manitoba, University of Calgary, Carleton University, and Loyalist College. Going forward, these education centres will make the Essential and Technical Skills Fundamentals courses available to students through a fully bilingual online learning platform...READ MORE

Chinook Therapeutics Announces the Appointment of Andrew Oxtoby as Chief Commercial Officer

Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced the appointment of Andrew Oxtoby as chief commercial officer. Andrew has over two decades of experience in the pharmaceutical and biotechnology industry, including extensive global experience involving numerous product launches across a wide array of therapeutic areas...READ MORE

Digital Supercluster Obtains $125M in New Funding

The Honourable François-Philippe Champagne, minister of Innovation, Science and Industry, announced that each of Canada’s Global Innovation Clusters will receive renewed support. The Digital Supercluster, headquarted in Vancouver and responsible for developing many healthcare I.T.-related applications, is receiving up to $125 million in renewed funding...READ MORE

Ipsen, UdeM and IRICoR Broaden Existing Oncology Partnership, With an Exclusive License Agreement and Two New Discovery-Stage Programs

Ipsen, Université de Montréal and IRICoR announce that Ipsen has exercised its option to acquire exclusive rights to a pre-clinical stage program with potential oncology applications. This license agreement is the result of a fruitful collaboration established between Ipsen, Université de Montréal and IRICoR in May 2020. Ipsen will now assume all development activities and commercialization of the drug candidate globally. Under the terms of the license agreement the Université de Montréal will receive an upfront payment and will be eligible to additional development and commercial milestones, as well as royalties on net sales...READ MORE

Canadian Alliance for Skills and Training in Life Sciences Partners With British Columbia Institute of Technology on New Biomanufacturing Training Facility

The Government of Canada and the Government of British Columbia announced a combined $7.2-million investment to create a new biomanufacturing training centre at BCIT, where in partnership with CASTL biomanufacturing training will be delivered to build the talent pool to meet the needs of the growing life sciences and biomanufacturing businesses. The new National Biomanufacturing Training Centre (NBTC) will be the first of its kind in B.C. It will give more people access to hands-on training courses to help them get skills for careers in life sciences and biomanufacturing...READ MORE

Gene Bio Medical Announces Revolutionary Molecular Imprint Diagnostic Solutions

Gene Bio Medical announce the release of its groundbreaking Molecular Imprint Diagnostic Solutions. This innovative technology is set to revolutionize the healthcare industry, providing advanced diagnostic solutions for the detection of diseases. Molecular imprinting is a technique that creates synthetic receptors or cavities on a molecular scale, enabling the recognition of target molecules with high selectivity and specificity. By utilizing this technique, Gene Bio Medical has developed a platform that offers unparalleled accuracy and sensitivity in the detection of diseases...READ MORE

NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

NervGen Pharma Corp., a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that all subjects (male, premenopausal and post-menopausal females) in the Phase 1 clinical trial of the Company’s proprietary lead compound, NVG-291, have completed dosing. The Company now plans to initiate a Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury in Q3 2023. NVG-291 has been demonstrated in preclinical studies to promote repair mechanisms in the nervous system, including axonal regeneration, remyelination and plasticity...READ MORE

PharmAla Biotech Closes Purchase Order With Emyria Ltd., Completes Filing of “LaNeo” Trademark in Australia

PharmAla Biotech Holdings Inc. announce that, in the wake of a landmark decision by the Therapeutic Goods Agency (“TGA”) of Australia on February 3rd, it has completed an agreement to sell a shipment of its GMP LaNeo MDMA to Emyria Ltd. Amidst growing interest in its products and technologies, PharmAla has submitted a trademark application for ‘LaNeo’ in Australia. The TGA’s regulatory change will make Australia the first country in the world to allow specially-licensed psychiatrists to prescribe MDMA and Psilocybin for certain conditions, beginning July 1st...READ MORE

Genome BC Invests $1.13 Million in Innovative Solution to Improve Surgical Care for Skeletal Traction

Genome British Columbia has invested $1.13 million into Arbutus Medical Inc., a BC-based medical device company developing innovative surgical drill technology and procedure kits that improve hospital workflow and reduce costs to treat patients. Matching funds have come from a syndicate of Canadian health tech and impact investment funds, including Nimbus Synergies, the Pan-Canadian consortium MEDTEQ+, and the ScaleGood Impact Fund. There is the potential of additional matching funds by the end of March 2023...READ MORE

Nimbus Synergies Co-Leads $2.26 Million Investment in Arbutus Medical to Accelerate Market Adoption of Skeletal Traction Innovation

Nimbus Synergies announce the completion of a $2.26 million follow-on investment in portfolio company Arbutus Medical. This investment was led by Nimbus Synergies and Genome BC’s Industry Innovation (I²) Fund to support the commercialization of Arbutus Medical’s TrakPak® – a complete single-use procedure kit that contains everything a surgeon needs for skeletal traction. Syndicate partners for this financing round included Canadian health tech and impact investment funds MEDTEQ Invest, ScaleGood Impact Fund, and ThresholdImpact...READ MORE

B.C. Building Talent Pool to Support Life Sciences, Biomanufacturing

More people will soon have access to hands-on training in a new state-of-the-art training centre to help them get skills for jobs in life sciences and biomanufacturing, supporting companies to help address some of the world’s most pressing health-care challenges. The Government of B.C. and PacifiCan are making a combined investment of $7.2 million to create a new B.C. National Biomanufacturing Training Centre (NBTC) at the British Columbia Institute of Technology (BCIT), which will support companies addressing some of the world’s most pressing health-care challenges...READ MORE

Canadian Health Science Innovations Attract Global Investment at the Sixth OBIO® Investment Summit

Global investors and strategic pharma licensing teams met with some of Canada’s most promising early-stage health science company leaders and our top research institutions at the OBIO® Investment Summit from February 8-10, 2023. The sixth edition of the annual Summit, held at First Canadian Place in Toronto, showcased Canada’s early-stage life science industry to the global investment community...READ MORE

Government of Canada Announces Renewed Funding for the Global Innovation Clusters

The Government of Canada is spurring economic growth, helping create well-paying jobs and growing our competitive advantage by investing in ideas, businesses and communities. Through the Global Innovation Clusters program, the government established a new approach to innovation: building accelerated and strong ecosystems in industries where Canada leads...READ MORE

Government of Canada Announces $5.2 Million to Boost. B.C. Clean Technology Sector

Pacific Economic Development Agency of Canada (PacifiCan), announced $5.2 million in funding through PacifiCan, together with $2.3 million from the Province of BC, for Foresight Canada. Foresight Canada will use this funding to establish the BC Net Zero Innovation Network (BCNZIN), bringing together innovators, businesses and stakeholders to accelerate the development of competitive cleantech solutions, and moving them to market. Foresight will initially focus on solutions for B.C.’s forestry, mining and water sectors...READ MORE

Scientist – Protein Biochemistry

Abdera Therapeutics is seeking a Scientist - Protein Biochemistry. Responsibilities include independently designing and executing experiments for the production, conjugation and biophysical characterization of antibodies. The position is also responsible for providing technical guidance and troubleshooting, intellectual input, and keep up to date with current and novel techniques, prepare and present data presentations and reports, work cross-functionally with other teams, CROs to efficiently and successfully deliver programs.

LEARN MORE

Postdoctoral Research Fellow, Brunham Laboratory

The Brunham Laboratory at the Centre for Heart Lung Innovation at UBC/St. Paul’s is currently seeking one full-time Postdoctoral Research Fellow with a Ph.D in Metabolism, Immunology, Genetics, Pharmacology, or a related field. Reporting to the PI, Dr. Liam Brunham, the successful candidate will conduct research in the area of lipid and lipoprotein metabolism in infections and sepsis using small animal models and in vitro approaches, as well as human genetics. A strong scientific background and excellent communication skills are required as the candidate will be part of a cross-faculty multi-disciplinary team.

LEARN MORE

Vice President, Intellectual Property

Xenon Pharmaceuticals is seeking a Vice President, Intellectual Property to join the team. The Vice President, Intellectual Property is responsible for leading and executing against the strategy for our intellectual property (IP) globally, including counseling management and colleagues on the legal implications of all corporate and business activities, developing and implementing legal strategies, leading a small team, and managing services provided by outside counsel. The individual serves as a member of the Chief Legal Officer’s leadership team.

LEARN MORE

Around the world, there are many health care challenges to solve. The population is growing and people are getting older, while more illnesses are on the rise. Traditional infections, together with welfare diseases such as cardiovascular diseases, obesity and diabetes, are putting huge pressure on health care. More people will need treatments, but there are fewer resources at hand.

Getinge is committed to meet those challenges together with health care providers and be part of improving patients’ lives around the globe. Their offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science.

Visit Website

Ahead of the curve starts here. The Digital Supercluster is building a better Canada by growing Canadian businesses, creating a digitally skilled workforce and positively impacting lives across our country. We accelerate the development and adoption of digital technologies that keep Canadians healthy, address climate change and drive economic productivity. Through a powerful combination of co-investment, cross-sector collaboration, IP creation and digital talent development, we unlock the potential of Canadians to lead and succeed in the digital world

Visit Website